Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd

HNGZY

$4.45

Updated: 22/09/2026, 17:58:39

Market Cap
$6.86B
Sector
Healthcare
Industry
Biotechnology
Country
CN
Stock valuation chart
One-year closing share-price history for HNGZY
Company Profile

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

USD
OTC
CEO: Xiao Chun Cao
Employees: 11,130
https://www.tigermedgrp.com
Asset Summaries
Latest generated summaries for HNGZY

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for HNGZY.
Share price
$4.45
Market cap
$6.86B
Exchange
OTC
Currency
USD
CEO
Xiao Chun Cao
Employees
11,130
IPO date
11/07/2022
Beta
0.405
Last dividend
$0.00
Day range
$4.20 – $4.45
52-week range
$4.00 – $4.45
1-day performance
0.00%
1-year performance
11.25%
Current drawdown (1Y)
0.00%
CIK
N/A
CUSIP
41044T108
ISIN
US41044T1088
Created
07/12/2025, 04:33:59
Last update
22/09/2026, 17:58:39

Track Hangzhou Tigermed Consulting Co., Ltd with an AI analyst

See which prediction-market events move HNGZY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to HNGZY from your Railway `news_articles` table.

No news found for this symbol.